2025 Q4 -tulosraportti
Vain PDF
89 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·49 min sitten · MuokattuThere is no holiday stop at Circio. All studies and tests continue as normal. How many they have internally or externally for whom they rent capacity in their own studies is not stated, but there are several. The collaboration partners in Germany, Canada, Spain, China, Japan, South Korea, USA are carrying out technology adaptations with circVec based on the collaboration agreements that have been entered into or are running their own studies. There is no stop anywhere. Management has had an enormous "rat race" for the last 6 months with the financing - 3 share issues, establishment of collaboration agreements, ASGCT presentation, participation in conferences, press coverage etc. They probably have a few weeks to catch their breath now to prepare for the most important autumn in the company's history. Soon they will return to review results that are produced every single day, to check readings, analyses of ongoing development and follow-up of agreements and technological collaboration. It is not little that is produced every single day in this increasingly comprehensive operation. At the same time, every single Big Pharma is pondering what they should do with the disruptive = revolutionary, groundbreaking and disturbing circVec technology, which challenges them in many fields within gene therapy, cell therapy, autoimmune diseases etc. When will they strike to secure circVec and in which area? Acquisitions and agreements in the preclinical phase are their new business model. Even the DNB analyst has seen this now, cf. fa.no.
·1 t sittenRef Aftenposten Jurassic Park star Sam Neill is dead The New Zealand actor Sam Neill is dead, 78 years old, his family informs. "The actor was diagnosed with non-Hodgkin lymphoma, a type of blood cancer, in 2022, something he spoke openly about. He also fought for more people to get access to CAR-T treatment." https://www.aftenposten.no/kultur/i/43Wv0g/jurassic-park-stjernen-sam-neill-er-doed?utm_source=iosapp&utm_medium=share AI * Sam Neill's story shows how important CAR-T has already become in the treatment of severe blood cancer. * CAR-T has established itself as one of the biggest medical breakthroughs in cancer treatment in recent years. * The increasing use of CAR-T underscores why next-generation cell therapies are one of the most attractive areas in biotech. * This is also why companies and Big Pharma are investing billions in developing safer and more accessible in vivo CAR-T solutions. * Circios' focus on in vivo CAR-T is therefore directed towards an area with both great medical need and significant commercial potential.
·2 t sittenAbsurd that it's allowed to go down so much... Pure bargain right now..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
89 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sitten · MuokattuThere is no holiday stop at Circio. All studies and tests continue as normal. How many they have internally or externally for whom they rent capacity in their own studies is not stated, but there are several. The collaboration partners in Germany, Canada, Spain, China, Japan, South Korea, USA are carrying out technology adaptations with circVec based on the collaboration agreements that have been entered into or are running their own studies. There is no stop anywhere. Management has had an enormous "rat race" for the last 6 months with the financing - 3 share issues, establishment of collaboration agreements, ASGCT presentation, participation in conferences, press coverage etc. They probably have a few weeks to catch their breath now to prepare for the most important autumn in the company's history. Soon they will return to review results that are produced every single day, to check readings, analyses of ongoing development and follow-up of agreements and technological collaboration. It is not little that is produced every single day in this increasingly comprehensive operation. At the same time, every single Big Pharma is pondering what they should do with the disruptive = revolutionary, groundbreaking and disturbing circVec technology, which challenges them in many fields within gene therapy, cell therapy, autoimmune diseases etc. When will they strike to secure circVec and in which area? Acquisitions and agreements in the preclinical phase are their new business model. Even the DNB analyst has seen this now, cf. fa.no.
- ·1 t sittenRef Aftenposten Jurassic Park star Sam Neill is dead The New Zealand actor Sam Neill is dead, 78 years old, his family informs. "The actor was diagnosed with non-Hodgkin lymphoma, a type of blood cancer, in 2022, something he spoke openly about. He also fought for more people to get access to CAR-T treatment." https://www.aftenposten.no/kultur/i/43Wv0g/jurassic-park-stjernen-sam-neill-er-doed?utm_source=iosapp&utm_medium=share AI * Sam Neill's story shows how important CAR-T has already become in the treatment of severe blood cancer. * CAR-T has established itself as one of the biggest medical breakthroughs in cancer treatment in recent years. * The increasing use of CAR-T underscores why next-generation cell therapies are one of the most attractive areas in biotech. * This is also why companies and Big Pharma are investing billions in developing safer and more accessible in vivo CAR-T solutions. * Circios' focus on in vivo CAR-T is therefore directed towards an area with both great medical need and significant commercial potential.
- ·2 t sittenAbsurd that it's allowed to go down so much... Pure bargain right now..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
89 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sitten · MuokattuThere is no holiday stop at Circio. All studies and tests continue as normal. How many they have internally or externally for whom they rent capacity in their own studies is not stated, but there are several. The collaboration partners in Germany, Canada, Spain, China, Japan, South Korea, USA are carrying out technology adaptations with circVec based on the collaboration agreements that have been entered into or are running their own studies. There is no stop anywhere. Management has had an enormous "rat race" for the last 6 months with the financing - 3 share issues, establishment of collaboration agreements, ASGCT presentation, participation in conferences, press coverage etc. They probably have a few weeks to catch their breath now to prepare for the most important autumn in the company's history. Soon they will return to review results that are produced every single day, to check readings, analyses of ongoing development and follow-up of agreements and technological collaboration. It is not little that is produced every single day in this increasingly comprehensive operation. At the same time, every single Big Pharma is pondering what they should do with the disruptive = revolutionary, groundbreaking and disturbing circVec technology, which challenges them in many fields within gene therapy, cell therapy, autoimmune diseases etc. When will they strike to secure circVec and in which area? Acquisitions and agreements in the preclinical phase are their new business model. Even the DNB analyst has seen this now, cf. fa.no.
- ·1 t sittenRef Aftenposten Jurassic Park star Sam Neill is dead The New Zealand actor Sam Neill is dead, 78 years old, his family informs. "The actor was diagnosed with non-Hodgkin lymphoma, a type of blood cancer, in 2022, something he spoke openly about. He also fought for more people to get access to CAR-T treatment." https://www.aftenposten.no/kultur/i/43Wv0g/jurassic-park-stjernen-sam-neill-er-doed?utm_source=iosapp&utm_medium=share AI * Sam Neill's story shows how important CAR-T has already become in the treatment of severe blood cancer. * CAR-T has established itself as one of the biggest medical breakthroughs in cancer treatment in recent years. * The increasing use of CAR-T underscores why next-generation cell therapies are one of the most attractive areas in biotech. * This is also why companies and Big Pharma are investing billions in developing safer and more accessible in vivo CAR-T solutions. * Circios' focus on in vivo CAR-T is therefore directed towards an area with both great medical need and significant commercial potential.
- ·2 t sittenAbsurd that it's allowed to go down so much... Pure bargain right now..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt